We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




First Direct Measurement of Dementia-Linked Proteins to Enable Early Alzheimer’s Detection

By LabMedica International staff writers
Posted on 10 Nov 2025

The disease process in Alzheimer’s begins long before memory loss or cognitive decline becomes apparent. More...

During this silent phase, misfolded proteins gradually form amyloid fibrils, which accumulate in the brain and cause irreversible damage. Current diagnostic techniques can rarely identify these early changes, meaning treatments often begin too late to be effective. Now, a breakthrough method could help detect the earliest stages of Alzheimer’s disease years before symptoms appear.

For the first time, researchers at Utrecht University (Utrecht, Netherlands) have made the growth of harmful protein clumps involved in dementias such as Alzheimer’s, Parkinson’s, and Huntington’s directly measurable — even in blood samples. The team, in collaboration with colleagues from international institutes, has developed FibrilPaint — a new class of molecules that “paint” the earliest fibril formations. FibrilPaint binds specifically to the thread-like amyloid protein aggregates characteristic of dementia and emits fluorescent light when exposed to specialized imaging equipment.

This fluorescence not only confirms the presence of the fibrils but also reveals their length and growth stage, offering a measurable indicator of disease progression. Importantly, FibrilPaint allows scientists to analyze blood and cerebrospinal fluid directly, eliminating the complex, time-consuming pretreatment steps required by existing methods.

The researchers believe FibrilPaint could revolutionize both early diagnosis and drug development for neurodegenerative diseases. By tracking disease progression in unprecedented detail, the technique, published in the journal PNAS, will allow clinicians to evaluate treatment effectiveness in real time.

“With our technique, we will soon be able to monitor the progression of the disease much more precisely and determine whether a treatment is effective,” said Françoise Dekker, a chemist at Utrecht University. “Our technique will eventually allow us to follow the course of the disease much more accurately and see whether a treatment really works.”

Related Links:
Utrecht University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.